AllStripes expands rare disease research programs to United Kingdom
February 12, 2021
We are thrilled to announce our first major expansion outside of North America: AllStripes is now live for research in the U.K., in addition to the U.S. and Canada.
Patients and caregivers based in the U.K. are now able to not only join the AllStripes platform, but receive all their medical records, at no cost, and contribute to our rare disease research programs from home.
“When it comes to rare disease, every patient is essential to our understanding of each condition and our ability to advance research,” said Nancy Yu, co-founder and chief executive officer of AllStripes. “We are thrilled to have received approval to expand our research into the U.K., which will enable deeper insights into the rare diseases impacting both local and global communities. This expansion opens the door for potential research collaborations that could reshape the way we’re treating patients.”
Going forward, we will seek out research collaborations with investigators in the U.K., the U.S., Canada and beyond. We hope to use our de-identified data insights and analysis to support submissions with the European Medicines Agency, in addition to the Food and Drug Administration here in the U.S., to benefit more patients around the world.
This expansion represents a significant milestone for us as a company and for the rare disease community. When it comes to rare disease, every patient’s experience is critical to better understanding each condition. This launch will open doors to improving research and ultimately help unlock new treatments.
Learn more and view our current research programs at allstripes.com.